Work

549O Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1740

Authors: M.S. Pelster, R. Yaeger, S.J. Klempner, S-H.I. Ou, A.I. Spira, P.A. Jänne, N.V. Uboha, Y.A. Gaffar, G. Newman, C.P. Paweletz, G.A. Heavey, L. Alejandro, T. Kheoh, K. Anderes, H. Der Torossian, J.G. Christensen, J. Weiss

Institutions: Sarah Cannon, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Virginia Cancer Specialists, The US Oncology Network, Dana-Farber Cancer Institute, University of Wisconsin–Madison, Maryland Oncology Hematology, Mirati Therapeutics (United States), University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Mirati Therapeutics

OpenAlex ID: W4387811799

FWCI: 0.62

Cites: 1

Cited by: 6

Related to: 10